Reneo Pharmaceuticals (RPHM) Stock Forecast, Price Target & Predictions
RPHM Stock Forecast
Reneo Pharmaceuticals stock forecast is as follows: a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
RPHM Analyst Ratings
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
May 17, 2022 | Piper Sandler | Overweight | Overweight | Hold |
Reneo Pharmaceuticals Financial Forecast
Reneo Pharmaceuticals Revenue Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - |
Avg Forecast | $15.96M | $7.97M | - | - | $100.25K | $27.25K | - |
High Forecast | $15.96M | $7.97M | - | - | $100.25K | $27.25K | - |
Low Forecast | $15.96M | $7.97M | - | - | $100.25K | $27.25K | - |
# Analysts | 1 | 1 | - | - | 1 | 1 | - |
Surprise % | - | - | - | - | - | - | - |
Reneo Pharmaceuticals EBITDA Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | - | - | 1 | 1 | - |
EBITDA | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Reneo Pharmaceuticals Net Income Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | - | - | 1 | 1 | - |
Net Income | - | - | - | - | - | - | - |
Avg Forecast | $-6.35M | $-10.34M | $-16.82M | $-18.83M | $-2.34M | $-2.34M | $-3.34M |
High Forecast | $-6.35M | $-10.34M | $-16.82M | $-18.83M | $-2.34M | $-2.34M | $-3.34M |
Low Forecast | $-6.35M | $-10.34M | $-16.82M | $-18.83M | $-2.34M | $-2.34M | $-3.34M |
Surprise % | - | - | - | - | - | - | - |
Reneo Pharmaceuticals SG&A Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | - | - | 1 | 1 | - |
SG&A | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Reneo Pharmaceuticals EPS Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | - | - | 1 | 1 | - |
EPS | - | - | - | - | - | - | - |
Avg Forecast | $-0.19 | $-0.31 | $-0.50 | $-0.56 | $-0.07 | $-0.07 | $-0.10 |
High Forecast | $-0.19 | $-0.31 | $-0.50 | $-0.56 | $-0.07 | $-0.07 | $-0.10 |
Low Forecast | $-0.19 | $-0.31 | $-0.50 | $-0.56 | $-0.07 | $-0.07 | $-0.10 |
Surprise % | - | - | - | - | - | - | - |
Reneo Pharmaceuticals Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
HEPA | Hepion Pharmaceuticals | $0.63 | $70.00 | 11011.11% | Buy |
KRON | Kronos Bio | $0.95 | $7.63 | 703.16% | Buy |
NKTX | Nkarta | $3.23 | $21.60 | 568.73% | Buy |
HOWL | Werewolf Therapeutics | $2.26 | $12.00 | 430.97% | Buy |
CNSP | CNS Pharmaceuticals | $0.11 | $0.50 | 354.55% | - |
IMMX | Immix Biopharma | $1.58 | $7.00 | 343.04% | Buy |
PRME | Prime Medicine | $3.96 | $17.25 | 335.61% | Buy |
VIR | Vir Bio | $9.37 | $26.60 | 183.88% | Buy |
APLS | Apellis Pharmaceuticals | $28.56 | $76.13 | 166.56% | Buy |
KZR | Kezar Life Sciences | $7.09 | $17.50 | 146.83% | Buy |
ADPT | Adaptive Bio | $5.26 | $12.33 | 134.41% | Hold |
CCCC | C4 Therapeutics | $6.45 | $13.50 | 109.30% | Buy |
CELC | Celcuity | $15.36 | $31.50 | 105.08% | Buy |
CGEM | Cullinan Oncology | $15.92 | $31.50 | 97.86% | Buy |
LEGN | Legend Biotech | $43.61 | $82.62 | 89.45% | Buy |
SMMT | Summit Therapeutics | $19.96 | $36.00 | 80.36% | Buy |
RPRX | Royalty Pharma | $27.20 | $43.33 | 59.30% | Buy |
EWTX | Edgewise Therapeutics | $34.48 | $45.00 | 30.51% | Buy |
RPHM | Reneo Pharmaceuticals | $18.20 | $18.00 | -1.10% | Buy |
DNA | Ginkgo Bioworks | $7.63 | $7.34 | -3.80% | Buy |
RPHM Forecast FAQ
Is Reneo Pharmaceuticals a good buy?
Yes, according to 1 Wall Street analysts, Reneo Pharmaceuticals (RPHM) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of RPHM's total ratings.
What are Reneo Pharmaceuticals's analysts' financial forecasts?
Reneo Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $127.5K (high $127.5K, low $127.5K), average EBITDA is $0 (high $0, low $0), average net income is $-8.021M (high $-8.021M, low $-8.021M), average SG&A $0 (high $0, low $0), and average EPS is $-0.24 (high $-0.24, low $-0.24). RPHM's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $23.93M (high $23.93M, low $23.93M), average EBITDA is $0 (high $0, low $0), average net income is $-52.334M (high $-52.334M, low $-52.334M), average SG&A $0 (high $0, low $0), and average EPS is $-1.566 (high $-1.566, low $-1.566).